CaixaResearch debate on fatty liver, a disease that affects more than a third of the population
Today, Thursday, February 8, at 19:00, the “la Caixa” Foundation organizes the CaixaResearch debate on fatty liver, the most common liver disease in the world, which experts already consider an epidemic.
Head of the Health Systems Research Group at the Barcelona Institute for Global Health (ISGlobal) and Associate Professor at the University of Barcelona (UB), Jeffrey W. Lazarus; group leader of the laboratory of complex metabolic diseases and mitochondria of the Institute of Biomedical Research (IRB Barcelona), coordinator of the CIBERDEM program and professor at UB, Antonio Zorzanoand Principal Investigator of the Diabetes and Metabolism Group of the Val d’Hebron Research Institute (VHIR), David Martinez Selvawill take part in this session to explain this disease where patients suffer from fat accumulation in the liver.
Approximately 25% of patients develop non-alcoholic steatohepatitiswhich is characterized liver inflammation and fibrosisand if not controlled, it can lead to serious pathologies such as liver cirrhosis or liver cancer.
Jeffrey W. Lazarus, a researcher at ISGlobal, a center supported by the La Caixa Foundation, is leading various international initiatives to raise awareness and agree on a global agenda of priority actions to combat the spread of this disease. Key priorities include collaboration between liver specialists and primary care physicians, and the development of different treatment strategies depending on the stage of the disease or the presence of multiple simultaneous diseases.
In addition, many researchers pay attention early diagnosis and in creating less invasive diagnostic methods. Currently liver biopsy This remains one of the most commonly used methods.
Researcher Antonio Zorzano is leading a project to find biomarkers of fatty liver disease that can help diagnose the disease non-invasively. His team has discovered a protein called mitofusin-2 present in the mitochondria of liver cells and is studying whether the protein can be used as a therapeutic target to develop new treatments. CaixaResearch helps with this Medical research worth about a million euros.
For their part, the team led by David Martinez Selva has identified two proteins that, when combined with a mathematical algorithm, can be used as a non-invasive biomarker to predict the development and progression of various stages of the disease, including the most severe ones. .
The project, which is supported by the CaixaImpulse Call for Innovation in Health, is working to accelerate the validation of this new biomarker and facilitate the development of new drugs to treat these conditions.
Fatty liver disease is associated with Unhealthy Lifestyle. In this regard, to prevent the disease or reverse its effects in the early stages, experts recommend:
To subscribe to streaming It’s necessary fill the form which is on the CaixaResearch website no later than one hour before the start.
IAG Group, which includes Iberia, British Airways, Vueling, Level and Aer Lingusmaintains the course for…
This mode allows your Mac to work harder. High performance mode is now available on…
Trainer Real Madrid, Carlo Ancelottinoted that they have a good opportunity to find their best…
MEOVV's Narin has been compared to Bella Poarch. Photo: Black Label On the afternoon of…
The Hague (EFE).- At least 62 people were arrested and 5 injured in Amsterdam this…
Artificial intelligence is already helping to search for new methods of treating cancer, diagnose tumors…